Bombay HC allows provisional release of Supriya Lifescience's Ketamine consignment
- Bombay High Court allowed provisional release of 200 kg Ketamine Hydrochloride consignment
- Release conditioned on depositing ₹72 lakh with customs authorities within one week
- Customs retains right to continue adjudication and criminal proceedings under NDPS Act
*this image is generated using AI for illustrative purposes only.
Supriya Lifescience Ltd received a favorable order from the Bombay High Court on September 22, 2026, permitting the provisional release of a seized consignment of 200 kg of Ketamine Hydrochloride. The court conditioned this release on the company depositing ₹72 lakh with the customs authorities within one week.
This development follows earlier disclosures made by the company in July and September 2026 regarding the detention of goods covered under Shipping Bill No. 3780061, dated June 2, 2026. The judicial order provides interim relief to the pharmaceutical manufacturer while legal proceedings remain active.
Court conditions and ongoing proceedings
The Hon'ble Court’s judgment clarified that while the physical goods can be provisionally released, the regulatory and criminal processes are not halted. Key directives from the order include:
- The company must deposit ₹72 lakh with the Assistant Commissioner of Customs, Export, ACC, Mumbai-III within seven days of the order date.
- Customs authorities retain the right to continue adjudication and criminal proceedings in accordance with existing laws.
- The concerned officer is permitted to follow procedures under Section 52A of the Narcotic Drugs and Psychotropic Substances (NDPS) Act.
Impact on operations
For Supriya Lifescience, the provisional release mitigates immediate operational disruption associated with the held inventory. However, the financial outlay of ₹72 lakh represents a short-term liquidity requirement. The company stated it will continue to monitor the matter closely and inform stock exchanges of any further developments or subsequent court orders as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What the Numbers Show
The order highlights a divergence between operational continuity and legal liability. While the ₹72 lakh deposit secures the physical return of the 200 kg consignment, the explicit permission for authorities to continue adjudication indicates that the final ownership and legality of the export remain unresolved. This suggests that the deposit serves as a security measure rather than a settlement, keeping the company exposed to potential future penalties or confiscation if the ongoing proceedings yield adverse outcomes.
Historical Stock Returns for Supriya Lifescience
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.67% | +12.35% | +22.04% | +68.26% | +31.59% | +151.50% |
What is the estimated timeline for the final adjudication of the customs proceedings, and how might the outcome impact Supriya Lifescience's balance sheet?
How does this incident affect the company's compliance rating with international regulatory bodies, potentially influencing future export licenses?
Are there indications that other pharmaceutical exporters are facing similar NDPS Act-related scrutiny, suggesting a broader sector-wide regulatory tightening?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
